A premier investigator in the areas of translational and clinical drug development, Dr. Hidalgo has been at the helm of the early clinical development of more than 50 new anticancer agents.
The innate immune system is the body’s first line of defense against invading pathogens, but there has been a lack of information on what a “healthy” innate immune system looks like.
A Graduate Medical Education Diversity Welcome Back was held on January 19, 2019 for residency applicants to programs across NewYork-Presbyterian Hospital/Weill Cornell Medical Center.
The ongoing program of interdisciplinary and multilevel mentoring teams will meet twice more in the spring of 2019; four meetings will be held during the 2019-2020 academic year.
The event was open to students, trainees and professionals in the fields of medicine, nursing, physician’s assistant, social work, administration, and more.
The award will fund her research study on Advance Care Planning and its critical connection to quality End-of-Life care.
The newsletter’s feature was in recognition of Dr. Lee’s pivotal abstract that presented an evaluation of the gut microbiota in 169 kidney transplant recipients.
This therapy is primarily being studied for resistant prostate cancer that has spread and/or has not responded to hormonal therapy.
A preeminent hematologist, neuroscientist, administrator, and educator, Dr. Hempstead’s distinguished career at Weill Cornell has spanned more than 30 years.
Dr. Weir's expertise includes treatment and symptom management for advanced lung disease, with an emphasis on compassionate care for the critically ill.
